MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

Ipsen SA.

Fechado

SetorFinanças

98.05 -0.31

Visão Geral

Variação de preço das ações

24h

Atual

Mín

96.1

Máximo

98.5

Indicadores-chave

By Trading Economics

Rendimento

-118M

114M

Vendas

71M

1.8B

P/E

Médio do Setor

21.241

20.525

Rendimento de Dividendos

1.54

Margem de lucro

6.249

Funcionários

5,358

EBITDA

228M

710M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+21.76% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.54%

4.36%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

7.5B

Abertura anterior

98.36

Fecho anterior

98.05

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Ipsen SA. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de dez. de 2024, 07:05 UTC

Conversa de Mercado

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparação entre Pares

Variação de preço

Ipsen SA. Previsão

Preço-alvo

By TipRanks

21.76% parte superior

Previsão para 12 meses

Média 119.75 EUR  21.76%

Máximo 145 EUR

Mínimo 100 EUR

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Ipsen SA. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

3

Comprar

4

Manter

1

Vender

Pontuação Técnica

By Trading Central

94.4 / 99.15Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.